Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 17/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5268379 | 1.00 | CTSK (0.50) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL14923592 | 0.94 | CTSK (0.56) | CTSKCTSS | |
| SCHEMBL14923701 | 0.88 | CTSK (0.48) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL5269469 | 0.84 | CTSK (0.51) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL5276500 | 0.84 | CTSK (0.51) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL5268067 | 0.84 | CTSK (0.51) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL30638293 | 0.83 | CTSK (0.50) | CTSKCTSS | |
| SCHEMBL28600066 | 0.83 | CTSK (0.50) | CTSKCTSS | |
| SCHEMBL10706331 | 0.83 | CTSK (0.50) | CTSKCTSS | |
| SCHEMBL28618599 | 0.83 | CTSK (0.50) | CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1287006-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2007-10-24 | — | — | EP | disclosed |
| US-7138547-B2 | Antitumoral compounds | PHARMA MAR, S.A. | 2006-11-21 | — | — | US | disclosed |
| US-20040048834-A1 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048834-A1 | Antitumoral compounds | HCCS, MSR1, SUCNR1 | CTSK 4264/4885CTSS 2159/4885CA1 973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.